Donepezil Market Outlook 2026–2030: Growth Trends, Market Dynamics And Emerging Opportunities
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Donepezil Market Value Growth And Long-Term Outlook
The donepezil market size has seen consistent growth in recent years. It is anticipated to increase from $1.04 billion in 2025 to $1.09 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.5%. This historical expansion can be attributed to an aging global population, the rising prevalence of Alzheimer’s disease, the widespread adoption of cholinesterase inhibitors, improved rates of dementia diagnosis, and the expansion of neurology treatment facilities.
The donepezil market size is anticipated to undergo consistent growth in the upcoming years. It is projected to expand to $1.3 billion by 2030, achieving a compound annual growth rate (CAGR) of 4.5%. This growth throughout the forecast period can be attributed to the rising global elderly population, increased awareness concerning early dementia treatment, growing demand for cost-effective generic medications, the expansion of home-based cognitive care services, and escalating healthcare expenditure on neurodegenerative conditions. Key trends expected during this period include the increasing long-term usage in Alzheimer’s disease management, a growing preference for oral cognitive enhancement therapies, rising demand for generic donepezil formulations, the broadening of treatment for mild to moderate Alzheimer’s cases, and an intensified focus on geriatric neurology care.
Get A Free Sample Report With In-Depth Market Insights:
Donepezil Market Expansion Drivers: What’s Shaping Future Growth?
The increasing prevalence of Alzheimer’s disease is anticipated to drive the expansion of the donepezil market going forward. Alzheimer’s disease is a progressive neurological condition characterized by the degeneration and death of brain cells, leading to memory loss, cognitive decline, and changes in behavior. The cases of Alzheimer’s disease are on the rise due to various reasons, including an aging population, overall population growth, lifestyle-related factors, an increase in chronic diseases, genetic predispositions, and environmental exposures. Donepezil serves as an effective symptomatic therapy for Alzheimer’s disease by enhancing cognitive function and daily living skills through its impact on acetylcholine levels in the brain. For instance, in May 2024, a report by the Alzheimer’s Association, a US-based nonprofit organization dedicated to Alzheimer’s care, support, and research, noted that the number of Americans aged 65 and older diagnosed with Alzheimer’s dementia increased from 6.5 million in 2022 to an estimated 6.9 million in 2024. Therefore, the rising incidence of Alzheimer’s is fueling the growth of the donepezil market.
Donepezil Market Segment Analysis: What Are The Core Market Categories?
The donepezil market covered in this report is segmented –
1) By Type: 5mg, 10mg, 23mg
2) By Route Of Administration: Oral, Transdermal
3) By Application: Hospitals, Clinics, Drugstore
Donepezil Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the donepezil market are prioritizing the creation of advanced drug delivery technologies, such as once-weekly and extended-release transdermal systems, to boost patient compliance and lessen treatment-related discomfort for Alzheimer’s patients. A donepezil transdermal system delivers the medication through the skin at a controlled rate, circumventing first-pass metabolism and reducing the incidence of gastrointestinal side effects often linked with oral dosing. For instance, in March 2024, Corium, Inc., a US-based biopharmaceutical company, launched its new-generation Adlarity formulation, featuring enhanced patch adhesion, improved skin tolerability, and a more stable 7-day release profile, which ensures uninterrupted therapeutic exposure. Corium designed this updated system to streamline Alzheimer’s care by easing the dosing burden and improving adherence for older adults who struggle with daily oral medication regimens.
Donepezil Market Top Companies Driving Competitive Growth
Major companies operating in the donepezil market are AbbVie Inc., Pfizer Inc., Teva Pharmaceutical Inc., Intas Pharmaceuticals Ltd., Mylan NV, Sandoz Group AG, Hetero Drugs Ltd., Sun Pharmaceutical Inc., Eisai Co. Ltd., Cipla Ltd., Dr Reddy’s Laboratories, Apotex Inc., H Lundbeck A/S, Zydus Cadila, Amneal Pharmaceuticals LLC, Torrent Pharmaceuticals Ltd, Alkem Laboratories Ltd., Jubilant Pharmova Ltd., Wockhardt Ltd., Luoxin Pharmaceuticals Group
View The Full Donepezil Market Report:
Donepezil Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the donepezil market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the donepezil market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
